Type 1 diabetes
Conditions
Interventions
None listed
Sponsors
Shinshu University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Type 1 diabetes treated sensor-augmented pump (2) Patients whose insulin pump will be changed to MiniMed 770G (3) 18 years and older (4) Patients with written consent
Exclusion criteria
Exclusion criteria: (1) Patients with cancer (2) Patients on steroid treatment (3) Persons deemed inappropriate by the Principal Investigator or Research Assistants
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percent change in sensor glucose level from 70 to 180 mg/dL of time at CGM between baseline and end of observation (after 24 weeks of switching). | — |
Secondary
| Measure | Time frame |
|---|---|
| (1) Change in each of the following items from baseline to the end of observation (after 24 weeks of changeover) HbA1c Percentage of time that sensor glucose level is higher than 181 mg/dL and higher than 251 mg/dL at CGM. Percentage of time that sensor glucose level is less than 70 mg/dL and less than 54 mg/dL at CGM. Average sensor glucose level and coefficient of variation during the period of CGM Number of hypoglycemia alerts and hyperglycemia alerts Average daily insulin dose and average daily basal insulin dose Scores of various questionnaires (CSII-QOL, DTSQ, PAID) (2) Amount of change in the percentage of HbA1c less than 7% achieved between baseline and the end of observation (after 24 weeks of switching) (3) Time of wearing CGM and using Hybrid closed-loop system | — |
Countries
Japan
Contacts
Public ContactSatoshi Kubota
Shinshu University Hospital Diabetes Endocrinology
Outcome results
None listed